10x Genomics, Inc. (TXG) stock
TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30106% above fair value
$54.99−3.20 (-5.50%)
Close on Nov 16, 2026Market cap $7.16BP/E –Yield –
10x Genomics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
10x Genomics's ebitda for the twelve months ending Sep 30, 2026 was -$33.01M. For fiscal 2025 it was -$24.79M. The highest annual figure on record is -$14.07M in fiscal 2017.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$24.79M | – |
| FY2024 | Dec 31, 2024 | -$158.68M | – |
| FY2023 | Dec 31, 2023 | -$229.82M | – |
| FY2022 | Dec 31, 2022 | -$142.58M | – |
| FY2021 | Dec 31, 2021 | -$31.14M | – |
| FY2020 | Dec 31, 2020 | -$520.13M | – |
| FY2019 | Dec 31, 2019 | -$23.51M | – |
| FY2018 | Dec 31, 2018 | -$106.86M | – |
| FY2017 | Dec 31, 2017 | -$14.07M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$6.55M | – |
| Q2 FY2026 | Jun 30, 2026 | -$9.89M | -126.1% |
| Q1 FY2026 | Mar 31, 2026 | -$7.09M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.48M | – |
| Q3 FY2025 | Sep 30, 2025 | -$21.95M | – |
| Q2 FY2025 | Jun 30, 2025 | $37.94M | – |
| Q1 FY2025 | Mar 31, 2025 | -$31.31M | – |
| Q4 FY2024 | Dec 31, 2024 | -$41.09M | – |
| Q3 FY2024 | Sep 30, 2024 | -$32.52M | – |
| Q2 FY2024 | Jun 30, 2024 | -$32.77M | – |
| Q1 FY2024 | Mar 31, 2024 | -$52.30M | – |
| Q4 FY2023 | Dec 31, 2023 | -$45.47M | – |
| Q3 FY2023 | Sep 30, 2023 | -$85.42M | – |
| Q2 FY2023 | Jun 30, 2023 | -$53.42M | – |
| Q1 FY2023 | Mar 31, 2023 | -$45.51M | – |
| Q4 FY2022 | Dec 31, 2022 | -$16.58M | – |
| Q3 FY2022 | Sep 30, 2022 | -$33.84M | – |
| Q2 FY2022 | Jun 30, 2022 | -$56.62M | – |
| Q1 FY2022 | Mar 31, 2022 | -$35.54M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.05M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.18M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.44M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.46M | – |
| Q4 FY2020 | Dec 31, 2020 | -$405.67M | – |
| Q3 FY2020 | Sep 30, 2020 | -$61.66M | – |
| Q2 FY2020 | Jun 30, 2020 | -$36.11M | – |
| Q1 FY2020 | Mar 31, 2020 | -$16.70M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.24M | – |
| Q3 FY2019 | Sep 30, 2019 | -$7.06M | – |
| Q2 FY2019 | Jun 30, 2019 | -$9.22M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.00M | – |
| Q4 FY2018 | Dec 31, 2018 | -$74.08M | – |
See a number that looks wrong?